Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAG · NASDAQ Global Market
+$2.32 today
Vol 1.55M · Avg 0.34M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
No return metrics data available.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Benny Sorensen | President, CEO & Director | $819,670.00 | — | 52 | — | — |
Mads Nikolaj Behrndt-Eriksen | CFO & GM | $689,142.00 | — | 43 | — | — |
Mads Behrndt | CFO & GM | $689,142.00 | — | 43 | — | — |
Catherine Madigan | Chief Medical Officer | $640,560.00 | — | 54 | — | — |
Cecile Bonvoisin | Senior Vice President of CMC & Manufacturing | — | — | — | — | — |
Ananthram Sreenivasa Murthy | Chief Operating Officer | — | — | 48 | — | — |
Tara O'Meara | Senior Vice President of Development Operations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
Competitors
Peer companies in the same sector
No competitor data available.
Who manages COAG?
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) lists 7 active executives. The top listed executive is Catherine Madigan, Chief Medical Officer.
Explore More
Continue the stock analysis
Jump to another research area for this company.